Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
As of today (2026-07-28), the Forward Annual Dividend Yield of Concord Biotech is 0.60%.
As of today (2026-07-28), the Trailing Annual Dividend Yield of Concord Biotech is 0.60%.
BOM:543960's Forward Dividend Yield % is ranked worse than 75.84% of 149
companies
in the Biotechnology industry
Industry Median: 1.35
vs BOM:543960: 0.60
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Concord Biotech Forward Dividend Yield % Related Terms
BOM:543960 vs VRTX, REGN, RVMD: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, Concord Biotech's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Concord Biotech Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Concord Biotech's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Concord Biotech's Forward Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Concord Biotech Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
INR 7.550000
2026-07-24
2026-07-24
2026-08-30
Cash Dividend
annually
INR:INR 1.000000
INR 10.700000
2025-09-03
2025-09-03
2025-09-22
Cash Dividend
annually
INR:INR 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Concord Biotech's Forward Annual Dividend Yield (%) for Today is calculated as
Forward Annual Dividend Yield
=
Forward Full Year Dividend
/
Current Share Price
=
7.55
/
1257.00
=
0.60 %
Current Share Price is ₹1257.00. Concord Biotech's Dividends per Share for the forward twelve months is calculated as ₹7.55 * 1 = ₹7.55.
Concord Biotech's Trailing Annual Dividend Yield (%) for Today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Forward Dividend Yield % of 0.60% mean?
Concord Biotech (BOM:543960) has a Forward Dividend Yield % of 0.60% as of Jul. 28, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Concord Biotech and its competitors. According to the industry distribution chart, Concord Biotech ranks #113 out of 149 companies in the Biotechnology industry, placing it in the top 75.8%.
Is Concord Biotech's Forward Dividend Yield % too high?
Concord Biotech's current Forward Dividend Yield % is 0.60%. The Biotechnology industry median Forward Dividend Yield % is 1.35. Concord Biotech's value of 0.60% is 55.6% below this industry median. Based on the distribution chart, Concord Biotech ranks #113 out of 149 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Concord Biotech has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Concord Biotech's Forward Dividend Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Concord Biotech ranks #113 out of 149 companies for Forward Dividend Yield %. This places Concord Biotech in the lower half of its industry. The industry median Forward Dividend Yield % is 1.35. Concord Biotech's value of 0.60% is 55.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.35, based on 149 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Concord Biotech's current Forward Dividend Yield % of 0.60% is 55.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Concord Biotech and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Concord Biotech's current Forward Dividend Yield % is 0.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Biotech stock overvalued right now?
Based on GuruFocus' analysis, Concord Biotech (BOM:543960) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,665.32, compared to a current price of ₹1,257.00 — trading 24.5% below its estimated fair value. The current Forward Dividend Yield % is 0.60% and 55.6% below the Biotechnology industry median of 1.35. Concord Biotech's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Concord Biotech (BOM:543960), the current Forward Dividend Yield % is 0.60% as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Concord Biotech (BOM:543960) Overvalued in 2026?
Based on GuruFocus' analysis, Concord Biotech stock appears to be undervalued.
The current stock price of ₹1,257.00 is trading 24.5% below its estimated GF Value™ of ₹1,665.32.
GuruFocus considers Concord Biotech to be Modestly Undervalued.
Key valuation signals for BOM:543960:
Forward Dividend Yield %: 0.60%
GF Value™: ₹1,665.32 vs. price of ₹1,257.00 (24.5% below fair value)
Industry Position: 55.6% below the Biotechnology median (#113 of 149)
No single metric tells the full story. See the BOM:543960 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products. Geographically Company operates in two segments within India and outside India, having majority revenue from India.
68GF Score
Get the complete analysis for BOM:543960
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543960 has been successfully added to your 
